PDGFRA and neoplasm: Approximately 85% of GISTs harbor mutually exclusive activating mutations in KIT (exons 9, 11, 13, 17) or PDGFRA (exons 12, 18), driving constitutive receptor tyrosine kinase (RTK) activation and tumor progression (3, 10).